Metraipolis › archive › dc_dfd50b4c3fd2

Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis — Europe PMC PMID:41728453

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41728453
DOI: 10.7759/cureus.102031
License (as archived): solo-consultazione
Archived: 2026-10-07T13:20:11.781Z
SHA-256 of the archived text: 02734893505d69037968e4c670d3262ad739eabea5b25eb308392b951a50e11f
Stable URL of this page: https://metraipolis.com/documento/dc_dfd50b4c3fd2

How to cite

Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis — Europe PMC PMID:41728453 — Europe PMC (en), https://europepmc.org/article/MED/41728453 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dfd50b4c3fd2 (Metraipolis archive dc_dfd50b4c3fd2, sha256 02734893505d69037968e4c670d3262ad739eabea5b25eb308392b951a50e11f)

BibTeX

@misc{dcdfd50b4c3fd2,
  title = {Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis — Europe PMC PMID:41728453},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41728453},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dfd50b4c3fd2; sha256 02734893505d69037968e4c670d3262ad739eabea5b25eb308392b951a50e11f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41728453. Agents can read the archived copy with the MCP tool read_document.